Analyst Activity – Leerink Swann Reiterates Market Perform on Celgene (NASDAQ:CELG)

24

Analyst Ratings For Celgene (NASDAQ:CELG)

Story continues below

Today, Leerink Swann reiterated its Market Perform rating on Celgene (NASDAQ:CELG).

There are 1 sell rating, 4 hold ratings, 23 buy ratings on the stock.

The current consensus rating on Celgene (NASDAQ:CELG) is Buy (Score: 2.79) with a consensus target price of $140.33 per share, a potential 10.93% upside.

Some recent analyst ratings include

  • 3/20/2017-Leerink Swann Reiterated Rating of Market Perform.
  • 3/8/2017-Cowen and Company Reiterated Rating of Outperform.
  • 3/2/2017-Cann Reiterated Rating of Positive .

Dividend information for Celgene (NASDAQ:CELG)

.
Recent Insider Trading Activity For Celgene (NASDAQ:CELG)
Celgene (NASDAQ:CELG) has insider ownership of 0.97% and institutional ownership of 77.68%.

  • On 3/1/2017 Rupert Vessey, Insider, sold 4,000 with an average share price of $124.42 per share and the total transaction amounting to $497,680.00. View SEC Filing
  • On 11/9/2016 Michael A Friedman, Director, sold 18,600 with an average share price of $116.10 per share and the total transaction amounting to $2,159,460.00. View SEC Filing
  • On 10/24/2016 Corp /De/ Celgene, Major Shareholder, bought 800,150 with an average share price of $14.00 per share and the total transaction amounting to $11,202,100.00. View SEC Filing
  • On 10/3/2016 Michael A Friedman, Director, sold 56,116 with an average share price of $103.66 per share and the total transaction amounting to $5,816,984.56. View SEC Filing
  • On 9/23/2016 Richard W Barker, Director, sold 20,000 with an average share price of $110.82 per share and the total transaction amounting to $2,216,400.00. View SEC Filing
  • On 9/15/2016 Gilla Kaplan, Director, sold 9,710 with an average share price of $106.44 per share and the total transaction amounting to $1,033,532.40. View SEC Filing
  • On 8/23/2016 James J Loughlin, Director, sold 27,500 with an average share price of $114.10 per share and the total transaction amounting to $3,137,750.00. View SEC Filing

About Celgene (NASDAQ:CELG)
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Recent Trading Activity for Celgene (NASDAQ:CELG)
Shares of Celgene closed the previous trading session at 126.51 up +0.74 0.59% with 2,878,400 shares trading hands.

An ad to help with our costs